Editorial [ Reducing Cardiovascular Risk: Is Low-Density Lipoprotein-Cholesterol (LDL-C) Lowering Enough? ]

Publisher： Bentham Science Publishers

E-ISSN： 1875-6212|10|2|173-177

ISSN： 1570-1611

Source： Current Vascular Pharmacology, Vol.10, Iss.2, 2012-03, pp. : 173-177

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lipoprotein(a) Interactions With Low‐Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS)

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 5, Iss. 4, 2016-04 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ezetimibe; More Than a Low Density Lipoprotein Cholesterol Lowering Drug? An Update After 4 Years

By  

Current Vascular Pharmacology, Vol. 9, Iss. 1, 2011-01 ,pp. : 62-86

Bentham Science Publishers

Access to resources Recommend Favorite

“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses

By  

Current Vascular Pharmacology, Vol. 9, Iss. 5, 2011-09 ,pp. : 533-571

Bentham Science Publishers

Access to resources Recommend Favorite

Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?

By Kostapanos Michael S   Mikhailidis Dimitri P   Elisaf Moses S  

Future Cardiology, Vol. 8, Iss. 6, 2012-11 ,pp. : 813-817

Future Medicine

Access to resources Recommend Favorite

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 5, Iss. 5, 2016-05 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite